Huang Y, Prasad M, Lemon W J, Hampel H, Wright F A, Kornacker K, LiVolsi V, Frankel W, Kloos R T, Eng C, Pellegata N S, de la Chapelle A
Human Cancer Genetics Program, Comprehensive Cancer Center, Department of Pathology, Divisions of Sensory Biophysics and Endocrinology and Nuclear Medicine, Ohio State University, Columbus, OH 43210, USA.
Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9. doi: 10.1073/pnas.251547398.
Papillary thyroid carcinoma (PTC) is clinically heterogeneous. Apart from an association with ionizing radiation, the etiology and molecular biology of PTC is poorly understood. We used oligo-based DNA arrays to study the expression profiles of eight matched pairs of normal thyroid and PTC tissues. Additional PTC tumors and other tissues were studied by reverse transcriptase-PCR and immunohistochemistry. The PTCs showed concordant expression of many genes and distinct clustered profiles. Genes with increased expression in PTC included many encoding adhesion and extracellular matrix proteins. Expression was increased in 8/8 tumors for 24 genes and in 7/8 tumors for 22 genes. Among these genes were several previously known to be overexpressed in PTC, such as MET, LGALS3, KRT19, DPP4, MDK, TIMP1, and FN1. The numerous additional genes include CITED1, CHI3L1, ODZ1, N33, SFTPB, and SCEL. Reverse transcriptase-PCR showed high expression of CITED1, CHI3L1, ODZ1, and SCEL in 6/6 additional PTCs. Immunohistochemical analysis detected CITED1 and SFTPB in 49/52 and 39/52 PTCs, respectively, but not in follicular thyroid carcinoma and normal thyroid tissue. Genes underexpressed in PTC included tumor suppressors, thyroid function-related proteins, and fatty acid binding proteins. Expression was decreased in 7/8 tumors for eight genes and decreased in 6/8 tumors for 19 genes. We conclude that, despite its clinical heterogeneity, PTC is characterized by consistent and specific molecular changes. These findings reveal clues to the molecular pathways involved in PTC and may provide biomarkers for clinical use.
甲状腺乳头状癌(PTC)在临床上具有异质性。除了与电离辐射有关外,PTC的病因和分子生物学仍知之甚少。我们使用基于寡核苷酸的DNA阵列研究了八对匹配的正常甲状腺组织和PTC组织的表达谱。通过逆转录聚合酶链反应(RT-PCR)和免疫组织化学对额外的PTC肿瘤和其他组织进行了研究。PTC显示出许多基因的一致表达和独特的聚类图谱。在PTC中表达增加的基因包括许多编码黏附蛋白和细胞外基质蛋白的基因。24个基因在8/8的肿瘤中表达增加,22个基因在7/8的肿瘤中表达增加。这些基因中包括一些先前已知在PTC中过表达的基因,如MET、LGALS3、KRT19、DPP4、MDK、TIMP1和FN1。众多其他基因包括CITED1、CHI3L1、ODZ1、N33、SFTPB和SCEL。RT-PCR显示,在另外6/6的PTC中,CITED1、CHI3L1、ODZ1和SCEL高表达。免疫组织化学分析分别在49/52和39/52的PTC中检测到CITED1和SFTPB,但在甲状腺滤泡癌和正常甲状腺组织中未检测到。在PTC中表达下调的基因包括肿瘤抑制因子、甲状腺功能相关蛋白和脂肪酸结合蛋白。八个基因在7/8的肿瘤中表达降低,19个基因在6/8的肿瘤中表达降低。我们得出结论,尽管PTC在临床上具有异质性,但其特征是一致且特定的分子变化。这些发现揭示了PTC相关分子途径的线索,并可能为临床应用提供生物标志物。